Small Molecules of the Month

July 2020
drughunter.com



A-1331852

First-in-class, bioavailable BCL-XL inhibitor
Oral efficacy in xenograft, led to ADC dev.
From SBDD of prior BH3 mimetics
ACS Med. Chem. Lett., Jul. 5, 2020
AbbVie, North Chicago, IL / Genentech



X-165

Potent, bioavailable autotaxin inhibitor
Orally active in fibrosis mod., Ph. I IND cleared
From 225M cmpd DNA-encoded library + opt.
J. Med. Chem., Jul. 23, 2020
X-Chem, Waltham, MA



HTL22562

Potent, non-oral CGRP antagonist
Clean profile in 10-day rodent tox.
From SBDD of prior ligand
J. Med. Chem., Jul. 23, 2020
Sosei Heptares, Cambridge, UK



MGS0274

Oral prodrug of mGlu2/3 receptor agonist
In development for schizophrenia
From derivatization of active molecule
Eur. J. Med. Chem., Jul. 5, 2020
Taisho Pharmaceutical, Saitama, JP



"compound 2"

Potent, oral heme-displacing IDO1 inhibitor
Low predicted human dose (<10 mg QD)
From ALIS mass-based binding screen + SBDD
ACS Med. Chem. Lett., Jul. 15, 2020
Merck & Co., Boston, MA



"compound 18"

Orally available fetal hemoglobin inducer
Oral induction of fetal hemoglobal in cyno
From phenotypic screen and ADME opt.
Bioorg. Med. Chem. Lett., Jul. 24, 2020
Daiichi-Sankyo, Tokyo, JP / Asubio



"compound 6g"

Potent and orally available SGLT1/2 dual inh.
Activity in diabetes glucose tolerance model
Based on natural product phlorizin
Bioorg. Med. Chem. Lett., Jul. 5, 2020
Janssen R&D, Spring House, PA.



dotinurad (FYU-981)

Uric acid uptake (URAT1 transporter) inhibitor
Approved as new uricosuric med. In JP
Optimized to avoid mitochondrial toxicity
ACS Med. Chem. Lett., Jul. 20, 2020
Fuji Yakuhin, Saitama, JP



"compound 38a"

Orally active ChemR23 GPCR inhibitor
Oral effects on dendritic cells in higher species
From cell-based screen and optimization
Bioorg. Med. Chem., Jul. 14, 2020
Kyowa Kirin, Shizuoka, JP



"compound 23"

Selective oral serine protease FXia inhibitor
Projected BID dosing in patients
From 1.8k cmpd protease inh. screen + SBDD
J. Med. Chem., Jun. 17, 2020
Novartis (NIBR), Basel, Switzerland



LXE408

Kinetoplastid-selective proteasome inhibitor
Oral antileishmanial in Ph. I in HV
From 3M cmpd antiprolif. screen + opt.
J. Med. Chem., Jul. 29, 2020
Novartis (GNF), San Diego, CA



AB680

Potent, selective, Q2W IV CD73 inhibitor
Completed Ph. I in HV, in dev. for cancer imm.
From opt. of known nucleotide CD73 inh.
J. Med. Chem., Jul. 20, 2020
Arcus Biosciences, Hayward, CA



ETX0282

Oral prodrug of serine β-lactamase inh.
In dev. for multidrug resistant bact. infection
From optimization of prior β-lactamase inh.
J. Med. Chem., Jul. 24, 2020
Entasis Therapeutics, Waltham, MA



EC2629

FR-targeted DNA crosslinking agent conjugate
Activity in xenograft w/ once weekly dosing
From conjugation of FR-ligand and PBD dimer
Sci. Rep., Jul. 29, 2020
Endocyte, West Lafayette, IN / Novartis

drug hunter